Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-09-27
2008-07-22
Badio, Barbara P (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S611000, C552S513000
Reexamination Certificate
active
07402577
ABSTRACT:
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.
REFERENCES:
patent: 4191759 (1980-03-01), Johnston et al.
patent: 5140106 (1992-08-01), Winterfeldt et al.
patent: 5371078 (1994-12-01), Clark et al.
patent: 5550134 (1996-08-01), Audia et al.
patent: 5565467 (1996-10-01), Batchelor et al.
patent: 5770592 (1998-06-01), Clark
patent: 5846976 (1998-12-01), Batchelor et al.
patent: 5990099 (1999-11-01), Clark
patent: 5998464 (1999-12-01), Bakshi et al.
patent: 6172054 (2001-01-01), Clark
patent: WO 94/03474 (1994-02-01), None
patent: WO 98/15568 (1998-04-01), None
patent: WO 98/25623 (1998-06-01), None
Physicians' Desk Reference(PDR), Edition 61, 2007, p. 1973, Montvale, NJ.
Negro-Vilar, Andres, The Journal of Clinical Endocrinology & Metabolism, “Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millenium,” 1999, pp. 3459-3462, vol. 84, No. 10, San Diego, CA.
Chang, C., “Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical Applications,” 2002, p. 279-288, Norwell, MA.
Duggan Mark E.
Wang Jiabing
Whitman David B.
Badio Barbara P
Camara Valerie J.
Merck & Co. , Inc.
Panzer Curtis C.
Shatynski Patricia A.
LandOfFree
Androstane 17-beta-carboxamides as androgen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Androstane 17-beta-carboxamides as androgen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Androstane 17-beta-carboxamides as androgen receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963174